Eriocalyxin B Inhibitor

Eriocalyxin B induces apoptosis and cell cycle arrest in pancreatic adenocarcinoma cells through caspase- and p53-dependent pathways, should be considered a candidate for pancreatic cancer treatment, it is a specific inhibitor of STAT3, it directly targets STAT3 through a covalent linkage to inhibit the phosphorylation and activation of STAT3 and induces apoptosis of STAT3-dependent tumor cells.

Eriocalyxin B ameliorates experimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells.Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2258-63.
Eriocalyxin B ameliorates experimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells.Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2258-63.
Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways.Exp Hematol. 2010 Mar;38(3):191-201.
Eriocalyxin B inhibits nuclear factor-kappaB activation by interfering with the binding of both p65 and p50 to the response element in a noncompetitive manner.Mol Pharmacol. 2006 Dec;70(6):1946-55.

Small volumes of Eriocalyxin B, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5760351 is an inhibitor targeting Eriocalyxin B.